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Abstract: Background: It is unclear whether exercise would reduce dementia in patients with a new
diagnosis of atrial fibrillation (AF). Therefore, we aimed to evaluate the association between the
change in physical activity (PA) before and after new-onset AF and the risk of incident dementia.
Methods: Using the Korean National Health Insurance Service database, we enrolled a total of
126,555 patients with newly diagnosed AF between 2010 and 2016, who underwent health exam-
inations within two years before and after their diagnosis of AF. The patients were divided into
four groups: persistent non-exercisers, exercise starters, exercise quitters, and exercise maintainers.
Results: Based on a total of 396,503 person-years of follow-up, 5943 patients were diagnosed with
dementia. Compared to persistent non-exercisers, exercise starters (adjusted hazard ratio (aHR) 0.87;
95% confidence interval (CI) 0.81–0.94), and exercise maintainers (aHR 0.66; 95% CI 0.61–0.72) showed
a lower risk of incident dementia; however, the risk was similar in exercise quitters (aHR 0.98; 95% CI
0.92–1.05) (p-trend < 0.001). There was a J-shaped relationship between the dose of exercise and the
risk of dementia, with the risk reduction maximized at 5–6 times per week of moderate-to-vigorous
PA among exercise starters. Conclusion: Patients who initiated or continued regular exercise after
diagnosis of AF were associated with a lower risk of dementia than persistent non-exercisers, with no
risk reduction associated with exercise cessation. Our findings may provide evidence for the benefit
of exercise prescription to patients with new-onset AF to prevent incident dementia regardless of
their current exercise status.
Keywords: atrial fibrillation; physical activity; dementia; prevention; cohort study; nationwide study
1. Introduction
The prevalence of atrial fibrillation (AF) is rapidly increasing with an aging population,
affecting 33.5 million people globally [1]. The lifetime prevalence in middle-aged adults
is reported to be 25% [2]. Numerous studies have found AF to be an independent risk
factor for dementia, [3] which is also a major public health issue worldwide. Furthermore,
dementia is associated with an increased risk of mortality in patients with AF [4]. Hence,
interventions to prevent dementia in patients with AF are needed; however, limited data
on lifestyle interventions are available.
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Physical activity (PA) has been proposed by the WHO to reduce the risk of dementia
in the general population [5]. However, recent prospective cohort studies and randomized
controlled trials have shown controversial results [6–10]. Since patients with AF are
prevalent, and they have a two-fold increased risk of developing cognitive decline and
dementia [11], this population should be considered separately from healthy controls.
Previous studies regarding exercise in patients with AF mostly focused on the improvement
of AF-related symptoms, quality of life, or exercise capacity [12–14]. AF burden was also
found to decrease with regular PA [14,15]; however, there is a paucity of data on whether
decreased AF burden resulting from PA could reduce incident dementia.
At the time that patients are newly diagnosed with AF, intensive lifestyle modification
could be a prescription for better clinical outcomes, including the prevention of incident
dementia. Based on a nationwide population-based cohort, we investigated the association
between the change in PA and incident dementia among patients newly diagnosed with AF.
2. Materials and Methods
2.1. Data Source and Study Population
We collected data from the Korean National Health Insurance Service (NHIS) database
from 1 January 2010 to 31 December 2016. The NHIS is a single Korean insurer covering
the entire Korean population [16], and the NHIS database contains all medical claims data
of the enrollees, including demographic variables, diagnosis based on International Classi-
fication of Diseases-10th Revision (ICD-10) codes, and prescription records. In addition,
NHIS enrollees are recommended to receive health examinations biennially; moreover,
comprehensive data from health examinations, including anthropometric measurements,
laboratory findings, and answers from a self-reported questionnaire about lifestyle behav-
ior, are added to the NHIS database. The NHIS cohort database has been used in numerous
high-quality research papers [17,18], and further details about the NHIS cohort and its
validity are available in a previous study [16]. The Institutional Review Board at the Seoul
National University Hospital (E-2001-110-1096) approved this study, and the need for
informed consent was waived since the NHIS provides anonymized data of its enrollees
and strictly follows the guidelines of the Personal Data Protection Act.
The flowchart of the study population enrollment is presented in Figure 1. Among the
523,174 patients newly diagnosed with AF between 2010 and 2016, patients with valvular
AF and aged under 20 years were excluded. We only included patients who underwent
health examinations within two years before and after their AF diagnosis and excluded
those with preexisting dementia. Finally, 126,555 patients were enrolled in the analysis.
2.2. Evaluation of Physical Activity
The level of PA was assessed based on a self-reported structured questionnaire, which
was utilized in several high-quality research papers [17,19]. The questionnaire documents
the frequencies of weekly PA of varying intensities classified as light, moderate, or vigorous
(Figure S1 in Supplementary Materials). Light-intensity PA was defined as walking at a
usual pace for a total of 30 min/day. Moderate-intensity PA (MPA) was defined as an
exercise that causes mild shortness of breath, such as brisk walking or bicycling, for a total
of 30 min/day. Vigorous-intensity PA (VPA) was defined as intense exercise causing more
shortness of breath than MPA, such as running, hiking, or bicycling at high speeds, for a
total of 20 min/day.
According to recent European and American guidelines on the prevention of cardiovas-
cular disease [20,21], we defined moderate to vigorous-intensity PA (MVPA) as performing
regular exercise. Thus, individuals performing at least 1 regular MVPA/week were defined
as an exerciser, and those with no MVPA/week were considered as a non-exerciser. For the
primary analysis, the study population was categorized into four groups based on their
consistency in performing regular exercise before and after AF diagnosis: [1] persistent
non-exercisers, [2] exercise starters, [3] exercise quitters, and [4] exercise maintainers.
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2.3. Covariates
We included the patients’ demographic variables, anthropometric measurements, co-
morbidities, medications, and health habits regarding drinking and smoking as covariates.
Demographic variables of age and sex and anthropometric measurements of body mass in-
dex were included. Comorbidities included hypertension, diabetes mellitus, dyslipidemia,
congestive heart failur , peripheral artery disease (PAD), previou myocardial infarction
(MI), previous stroke, chronic obstructive pulmonary disease (COPD), chronic kidney
disease (CKD), cancer, and CHA2DS2-VASc score. The use of medications, including oral
anticoagulants (OACs), antiplatelet agents, and statins, were included. Low-income levels,
smoking status, and drinking habits were also used. Detailed information about covariates
is summarized in Table S1.
2.4. Study Outcomes and Follow-Up
Th primary outcome was incident dementia. D mentia was furth r classified into
Alzheimer’s dementia, vascular dementia, and other types of dementia. The definition of
each dementia is presented in Table S1. The date of the second health examination was
defined as an index date, and patients were followed up until the occurrence of the primary
outcome or 31 December 2016, whichever came first (Figure S2).
2.5. Statistical Analysis
Baseline characteristics of patients were calculated using n (%) for categorical variables
and mean ± standard deviation (SD) for continuous variables. The incidence rate (IR) was
calculated based on incidence per 1000 person-years (PY), and hazard ratio (HR) and 95%
J. Clin. Med. 2021, 10, 3126 4 of 12
confidence intervals (95% CI) for the risk of incident dementia were calculated using the Cox
proportional hazards model. We used the persistent non-exerciser group as the reference
group to calculate the HR of incident dementia among different PA groups. Multivariable
regression models were constructed with adjustment for the following variables: (i) age
and sex and (ii) age, sex, body mass index, smoking habits, drinking habits, income levels,
hypertension, diabetes mellitus, dyslipidemia, congestive heart failure, PAD, previous
MI, previous stroke, COPD, CKD, cancer, CHA2DS2-VASc score, and the use of OACs,
antiplatelet agents, and statins.
We conducted an additional landmark analysis for two reasons. First, to minimize the
possibility of reversed-causality since dementia is well known to have a long preclinical
phase, and being physically inactive can be an early manifestation of dementia [22]. Second,
we needed to determine whether continuing exercise for a long period could affect the
development of dementia. In the landmark analysis, we excluded patients who developed
incident dementia between the index date and the landmark time point. Two landmark
time points of one and three years were used.
For subgroup analyses, we stratified the study population by sex, age group (<65,
65–74, and ≥75 years), and CHA2DS2-VASc score (<3 and ≥3 points). Subgroup analyses
based on the presence of a history of stroke, the use of OACs, and the use of statins were
also conducted since these factors are associated with the development of dementia in
patients with AF [23–25]. p-for-trend and p-for-interaction were computed to find the
intragroup and intergroup differences. To identify the optimal dose of PA for a lower risk
of incident dementia, we further stratified the exercise starter group into four subgroups
by the frequency of MVPA/week, which is a summation of the days of weekly MPA and
VPA: 1-2/week, 3–4/week, 5–6/week, and ≥7/week. We used the same multivariable
Cox regression models used in the primary analysis. All analyses were two-tailed, and
statistical significance was defined as a p-value < 0.05. Statistical analyses were performed
using SAS 9.4 (SAS Institute, Cary, NC, USA). The data underlying this article will be
shared on reasonable request to the corresponding author.
3. Results
3.1. Baseline Characteristics
A total of 126,555 patients were included in this study. The baseline characteristics of
each group are shown in Table 1.
Exercise quitters performed a median of 4 MVPAs/week before their AF diagnosis
(interquartile range (IQR), 2–6 MVPAs/week), while exercise starters initiated a median of
4 MVPAs/week after AF diagnosis (IQR, 2–6 MVPAs/week). Exercise maintainers also
performed a median of 4 MVPAs/week before and after their diagnosis of AF (IQR, 2–7
and 3–7 MVPAs/week, respectively).
3.2. Changes in PA before and after New AF Diagnosis and the Risk of Incident Dementia
During a mean follow-up of 3.1 ± 1.9 years (total 396,503 PY), 5943 patients were newly
diagnosed with dementia (IR 15.0/1000 PY). Among 5943 patients, 4410 were diagnosed
with Alzheimer’s dementia, and 951 were diagnosed with vascular dementia (IR 11.1/1000
PY and 2.4/1000 PY, respectively).
Compared with persistent non-exercisers, exercise maintainers were associated with a
lower risk of overall dementia, Alzheimer’s dementia, and vascular dementia. Exercise
starters also showed lower risks; however, there were no differences in the risk of dementia
between persistent non-exercisers and exercise quitters (Figure 2). Crude event numbers,
IRs, and HRs for overall dementia, Alzheimer’s dementia, and vascular dementia are
presented in Table S2.
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Table 1. Baseline characteristics.











Age, years 62.7 ± 12.0 65.7 ± 11.5 65.2 ± 12.0 63.6 ± 11.6 59.1 ± 11.8
<65—no. (%) 64,503 (51.0%) 17,188 (40.1%) 11,689 (52.8%) 10,939 (47.6%) 24,687 (64.1%)
65–74—no. (%) 41,349 (32.7%) 15,424 (36.0%) 7181 (32.4%) 8091 (35.2%) 10,653 (27.7%)
≥75—no. (%) 20,703 (16.4%) 10,272 (24.0%) 3280 (14.8%) 3963 (17.2%) 3188 (8.3%)
Male sex (%) 78,446 (62.0%) 21,819 (50.9%) 13,537 (61.1%) 14,103 (61.3%) 28,987 (75.2%)
Comorbidities
Hypertension 84,014 (66.4%) 29,468 (68.7%) 14,584 (65.8%) 15,432 (67.1%) 24,530 (63.7%)
Diabetes 29,024 (22.9%) 10,655 (24.9%) 5012 (22.6%) 5559 (24.2%) 7798 (20.2%)
Dyslipidemia 13,218 (10.4%) 4492 (10.5%) 2318 (10.5%) 2462 (10.7%) 3946 (10.2%)
Previous MI 6458 (5.1%) 2391 (5.6%) 1126 (5.1%) 1172 (5.1%) 1769 (4.6%)
Previous stroke 16,800 (13.3%) 6350 (14.8%) 2864 (12.9%) 3267 (14.2%) 4319 (11.2%)
Previous CHF 31,306 (24.7%) 11,896 (27.7%) 5285 (23.9%) 5904 (25.7%) 8221 (21.3%)
PAD 27,380 (21.6%) 10,552 (24.6%) 4829 (21.8%) 5318 (23.1%) 6681 (17.3%)
COPD 24,605 (19.4%) 9785 (22.8%) 4327 (19.5%) 4691 (20.4%) 5802 (15.1%)
Cancer 7253 (5.73%) 2344 (5.5%) 1363 (6.2%) 1435 (6.2%) 2111 (5.5%)
CKD 18,868 (14.9%) 7951 (18.5%) 3046 (13.8%) 3616 (15.7%) 4255 (11.0%)
CHA2DS2-VASc score 2.7 ± 1.7 3.2 ± 1.8 2.7 ± 1.7 2.9 ± 1.7 2.2 ± 1.5
0 8238 (6.5%) 1700 (4.0%) 1382 (6.2%) 1272 (5.5%) 3884 (10.1%)
1 25,590 (20.2%) 6242 (14.6%) 4537 (20.5%) 4247 (18.5%) 10,564 (27.4%)
2 28,568 (22.6%) 8498 (19.8%) 5277 (23.8%) 5122 (22.3%) 9671 (25.1%)
≥3 64,159 (50.7%) 26,444 (61.6%) 10,954 (49.5%) 12,352 (53.7%) 14,409 (37.4%)
Medication use
OACs
Warfarin 26,185 (20.7%) 8941 (20.9%) 4542 (20.5%) 4997 (21.7%) 7705 (20.0%)
NOACs 12,307 (9.7%) 4523 (10.6%) 2063 (9.3%) 2348 (10.2%) 3373 (8.8%)
Antiplatelet agent
Aspirin 26,752 (21.1%) 9572 (22.3%) 4508 (20.4%) 4955 (21.6%) 7717 (20.0%)
Clopidogrel 8865 (7.0%) 3277 (7.6%) 1525 (6.9%) 1717 (7.5%) 2346 (6.1%)
Statin 23,538 (18.6%) 8466 (19.7%) 4130 (18.7%) 4367 (19.0%) 6575 (17.1%)
Anthropometric measurements
Weight (kg) 65.3 ± 11.7 62.7 ± 11.5 65.3 ± 11.6 65.0 ± 11.5 68.3 ± 11.5
Height (cm) 162.8 ± 9.4 160.0 ± 9.5 162.8 ± 9.2 162.5 ± 9.2 166.1 ± 8.5
Waist circumference (cm) 84.6 ± 9.4 84.3 ± 10.3 84.4 ± 9.1 84.7 ± 9.0 84.8 ± 8.6
BMI (kg/m2) 24.6 ± 3.3 24.4 ± 3.5 24.6 ± 3.3 24.5 ± 3.3 24.7 ± 3.1
Systolic BP (mmHg) 125.7 ± 15.4 126.5 ± 16.0 125.6 ± 15.4 125.9 ± 15.7 124.9 ± 14.7
Diastolic BP (mmHg) 77.1 ± 10.3 77.1 ± 10.5 77.0 ± 10.2 77.0 ± 10.4 77.1 ± 10.1
Laboratory Findings
Fasting glucose (mg/dL) 105.0 ± 27.3 105.4 ± 28.8 104.7 ± 27.1 105.5 ± 27.5 104.2 ± 25.6
Triglyceride (mg/dL) 132.9 ± 91.2 134.1 ± 88.5 132.6 ± 93.4 132.9 ± 88.9 131.7 ± 94.3
Total cholesterol (mg/dL) 81.0 ± 40.7 180.6 ± 40.5 181.4 ± 43.7 180.3 ± 41.4 181.8 ± 38.7
HDL-cholesterol (mg/dL) 52.2 ± 15.0 51.9 ± 14.6 52.3 ± 15.3 51.8 ± 16.2 52.7 ± 14.6
LDL-cholesterol (mg/dL) 103.2 ± 41.1 102.5 ± 38.9 103.6 ± 45.1 103.1 ± 45.7 103.7 ± 38.2
AST (mg/dL) 27.9 ± 19.0 27.8 ± 22.2 27.9 ± 16.7 27.9 ± 17.8 27.9 ± 16.9
ALT (mg/dL) 25.9 ± 20.8 24.9 ± 19.5 26.1 ± 19.4 25.8 ± 19.3 27.1 ± 23.7
GGT (mg/dL) 44.8 ± 60.7 43.3 ± 62.0 44.2 ± 58.8 45.3 ± 62.4 46.5 ± 59.4
GFR (mL/min/1.73 m2) 80.3 ± 28.1 78.7 ± 27.4 81.2 ± 29.7 79.9 ± 28.4 81.8 ± 27.7
Lifestyle factors
Alcohol
Non-drinker 84,398 (66.7%) 32,752 (76.4%) 14,644 (66.1%) 16,271 (70.8%) 20,731 (53.8%)
Mild-moderate drinker 34,842 (27.5%) 7986 (18.6%) 6272 (28.3%) 5446 (23.7%) 15,138 (39.3%)
Heavy drinker 7315 (5.8%) 2146 (5.0%) 1234 (5.6%) 1276 (5.6%) 2659 (6.9%)
Smoking
Never smoker 75,061 (59.3%) 29,084 (67.8%) 13,092 (59.1%) 14,215 (61.8%) 18,670 (48.5%)
Ex-smoker 34,365 (27.2%) 8311 (19.4%) 5986 (27.0%) 5764 (25.1%) 14,304 (37.1%)
Current smoker 17,129 (13.5%) 5489 (12.8%) 3072 (13.9%) 3014 (13.1%) 5554 (14.4%)
Low income 21,262 (16.8%) 7876 (18.4%) 3759 (17.0%) 4018 (17.5%) 5609 (14.6%)
Follow-up duration 3.1 ± 1.9 3.1 ± 1.9 3.2 ± 1.9 3.2 ± 1.9 3.2 ± 1.9
SD, standard deviation; MI, myocardial infarction; CHF, congestive heart failure; CKD, chronic kidney disease; OACs, oral anticoagulants;
NOACs, non-vitamin K antagonist oral anticoagulants; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; AST, aspartate transaminase; ALT, alanine transaminase; GGT, gamma-glutamyl transferase; GFR, glomerular
filtration rate.
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3.3. Sensitivity Analyses: One-Year and Three-Year Landmark Analysis
Sensitivity analyses showed consistent findings with the main results (Table 2). In both
the one-year and three-year landmark analyses, the risk of incident dementia of exercise
quitters was similar to that of persistent non-exercisers. However, the risk of exercise
starters and exercise maintainers were lower than those of persistent non-exercisers in both
landmark analyses.
Table 2. The landmark analysis of one-year and three-year compared with the primary outcome.
Physical Activity Primary Outcome 1-Year Landmark Analysis a 3-Year Landmark Analysis b
Overall Dementia
Persistent non-exerciser 1 (Ref.) 1 (Ref.) 1 (Ref.)
Exercise starter 0.87 (0.81–0.94) 0.83 (0.76–0.91) 0.80 (0.70–0.91)
Exercise quitter 0.98 (0.92–1.05) 0.96 (0.89–1.04) 1.02 (0.91–1.15)
Exercise maintainer 0.66 (0.61–0.72) 0.66 (0.60–0.73) 0.65 (0.56–0.74)
p-trend <0.001 p-trend <0.001 p-trend <0.001
Alzheimer’s Dementia
Persistent non-exerciser 1 (Ref.) 1 (Ref.) 1 (Ref.)
Exercise starter 0.88 (0.80–0.95) 0.84 (0.76–0.93) 0.80 (0.69–0.94)
Exercise quitter 0.98 (0.91–1.06) 0.96 (0.88–1.05) 1.03 (0.90–1.18)
Exercise maintainer 0.65 (0.59–0.72) 0.65 (0.58–0.72) 0.66 (0.56–0.77)
p-trend <0.001 p-trend <0.001 p-trend <0.001
Vascular Dementia
Persistent non-exerciser 1 (Ref.) 1 (Ref.) 1 (Ref.)
Exercise starter 0.87 (0.72–1.05) 0.76 (0.61–0.95) 0.61 (0.43–0.88)
Exercise quitter 0.97 (0.82–1.15) 0.93 (0.77–1.13) 0.89 (0.66–1.20)
Exercise maintainer 0.71 (0.59–0.86) 0.70 (0.57–0.87) 0.56 (0.40–0.79)
p-trend = 0.004 p-trend = 0.004 p-trend = 0.002
HR is adjusted for age, sex, body mass index, smoking habits, drinking habits, income level, hypertension, diabetes mellitus, dyslipidemia,
previous myocardial infarction, previous stroke, previous congestive heart failure, peripheral artery disease, chronic obstructive pulmonary
disease, chronic kidney disease, cancer, and the use of warfarin, non-vitamin K antagonist oral anticoagulants, aspirin, clopidogrel, and
statin. a 1-year landmark analysis: excluded patients who developed dementia within 1 year after AF diagnosis. b 3-year landmark analysis:
excluded patients who developed dementia within 3 years after AF diagnosis.
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3.4. Subgroup Analyses
(a) Sex: There was no significant interaction between sex and change of PA in the risk
of overall dementia and Alzheimer’s dementia except for vascular dementia (Table S3).
In the male subgroup, exercise maintainers showed a lower risk of vascular dementia
(p-for-trend < 0.001), which was largely in line with the main results. However, there was
no significant difference in the risk of vascular dementia in the female subgroup based on
the PA groups (p-for-trend = 0.165).
(b) Age (<65, 65–74, and ≥75 years): In all age subgroups, consistent findings with the
primary analysis were observed (Table S4). There were significant interactions between
age and the risk of incident dementia based on PA groups (p-for-interaction = 0.006), and
the beneficial effects of starting and maintaining exercise after AF diagnosis were more
accentuated in patients aged <65 years.
(c) CHA2DS2-VASc score (<3 and ≥3): There were significant interactions between
CHA2DS2-VASc scores of <3 and ≥3 and the risk of incident dementia based on PA groups
(p-for-interaction = 0.008). The positive effect of exercise maintenance was more accentuated
in patients with CHA2DS2-VASc scores of <3 (Table S5). In the subgroup of CHA2DS2-VASc
scores of <3, exercise starters did not show a lower risk of overall dementia, possibly due
to a lower incidence of dementia in this subgroup.
(d) History of stroke: The incidence rate of overall dementia was significantly higher
in patients with a history of stroke. Although p-for-interaction between the presence of
prior stroke and the exercise groups was statistically significant (p-for-interaction = 0.048),
the exercise starters and maintainers were associated with lower risks of incident dementia
regardless of the presence of a previous history of stroke (Table S6).
(e) Use of OACs: There was no significant interaction between the PA groups and
the use of OACs (Table S7). However, the risk reduction of incident dementia through
starting or maintaining exercise was slightly attenuated in the subgroup treated with OACs
compared with those who were not on OACs.
(f) Use of statins: There was no significant interaction between PA groups and the use
of statins (Table S8).
(g) Optimal dose of physical activity in exercise starters: Overall, the association
between the dose of MVPA/week and the risk of dementia showed a J-shaped relationship:
those with MVPAs of 5–6/week were associated with the lowest risk for developing
dementia (adjusted HR 0.74, 95% CI 0.61–0.89). For Alzheimer’s dementia, the results were
consistent with overall dementia. For the risk of vascular dementia, those with MVPAs
of 3–4/week (adjusted HR 0.56, 95% CI 0.3–0.84) were associated with the lowest risk
(Figure 3 and Table S9).
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4. Discussion
In this large nationwide, population-based cohort study, we demonstrated that starting
and maintaining exercise after AF diagnosis is associated with a significantly lower risk
of incident dementia. It is also important to note that exercise quitters had a similar risk
of incident dementia as persistent non-exercisers, further emphasizing the importance
of exercise prescription after a new diagnosis of AF for both non-exercisers and current-
exercisers. To the best of our knowledge, this is the first evidence of the beneficial effect of
PA on dementia in the AF population.
At least 3 MVPAs/week were required to reduce incident dementia, and 5–6 MV-
PAs/week were associated with the lowest risk. These results are largely in line with
guidelines for the general population provided by the European and American societies,
which recommend 150 min/week of MPA or 75 min/week of VPA or an equivalent combi-
nation [20,21]. In the landmark analyses, only exercise starters showed a gradual decrease
in the risk of incident dementia along with longer landmark periods. This finding suggests
that once an exercise regime is initiated, an individual that continues to exercise might
continuously be at a reduced risk of dementia. Meanwhile, exercise quitters showed a
similar risk of incident dementia even in the landmark analyses.
In the subgroup analysis, the risk reduction was more accentuated in female exercise
starters and male exercise maintainers, mainly due to significant interaction found in
vascular dementia. We need careful interpretation in this finding due to a relatively large
proportion of persistent non-exercisers in the female subgroup. Also, the event numbers
of vascular dementia were small in both sexes. This result is in line with the previous
prospective cohort study, which reported smaller relative risks of stroke in women than in
men who performed the same hours of exercise although the investigators did not focus on
the significance of this difference [26]. Considering the relatively less socially and culturally
active lifestyle in middle-to-old aged women in Korea, they might see greater benefits
from starting MVPA. However, male exercise maintainers performed more exercise than
female exercise maintainers, which led to a lower risk of dementia in the male subgroup.
Further study would be needed to clarify these differences. On the other hand, not only
the objectively lower incidence but also the risk reduction of dementia through exercise
were significant in the younger and less-diseased patients. Exercise activates neurogenesis
and synaptogenesis, which could improve memory and cognitive function [27]. Thus,
less significant risk reductions found in the older and more diseased patients might be
attributed to their decreased synthetic function. Based on these findings, exercise should be
encouraged paradoxically to the more fit and younger individuals when they are diagnosed
with AF. All the subgroups stratified by prior stroke, OACs, or statins showed a consistent
result with the primary outcome.
A large volume of the literature has consistently reported an increased risk of dementia
in the AF population [3,11]. Considering the high prevalence and rapidly increasing
incidence of AF, there is an increasing demand for interventions that can reduce the
socioeconomic and health burden caused by AF. Several studies have reported that the
long-term use of statins and anticoagulation therapy are associated with a lower risk of
dementia in patients with AF [24,25]. Yet, the effect of lifestyle modification on the risk of
dementia in patients with AF is not well reported.
Various high-quality research were conducted regarding the association between
PA and dementia but were mainly on a healthy population, and even the results were
conflicting; some studies have shown favorable outcomes with PA [6–8], while other studies
obtained neutral results [9], and even greater cognitive decline was observed in patients
who began to participate in the exercise program [10]. Though previous studies on healthy
populations are conflicting, several plausible mechanisms could explain our findings on
patients with AF.
First, the AF burden modulated by exercise might influence cognitive function. The
ARIC study reported that a higher AF burden is associated with a lower cognitive func-
tion [28], and the CARDIO-FIT (Cardiorespiratory Fitness on Arrhythmia Recurrence in
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Obese Individuals with Atrial Fibrillation) study [14] reported that exercise significantly
reduced AF burden. Furthermore, regular exercise might reduce body weight with a
consequence of reduced AF burden [29]. Taken altogether, regular exercise might reduce
the burden of AF with a consequent reduction in the risk of dementia. Second, patients
with AF have a lower cardiac index than patients with normal sinus rhythm [30], and
patients with low cardiac index are known to have an increased risk of dementia and
Alzheimer’s dementia [31]. Therefore, increased cerebral blood flow owing to exercise
itself [32] and improvement of left ventricular ejection fraction as a consequence of exercise
in AF patients [33] might attribute to a lower risk of dementia.
4.1. Strengths
Our study has several strengths. First, our novel evidence was based on a large, nation-
wide, observational cohort. It is also important to note that we applied no strict inclusion or
exclusion criteria, thereby recruiting as many patients as possible and minimizing selection
bias. In addition, we collected the level of PA at two different time points before and after a
new AF diagnosis, which differentiates our study from previous research [7,15] given that
prior studies have only provided exercise-related information at a single time point. This is
important since PA in the elderly is prone to change, resulting from illness or disability,
and AF is one of the major factors that can limit exercise tolerance. Hence, collecting the
exercise status at two different time points is especially important in differentiating exercise
starters from persistent non-exercisers and exercise maintainers from exercise quitters.
Furthermore, we added two more time points by conducting one-year and three-year
landmark analyses, and the results further strengthened the primary results, minimizing
the possibility of reversed-causality and highlighting the importance of starting and not
quitting exercise.
4.2. Limitations
There are several limitations to this study. First, the study cannot show cause-and-
effect relationship due to limitations inherent to the retrospective design. Second, the
level of PA was evaluated by self-reported questionnaires, which inevitably accompanies
recall bias. Therefore, we defined exercise as at least one regular MVPA/week, which is
the most intuitive criterion that can discriminate people who intentionally exercise from
those who perform only light-intensity daily activities. Third, the effect of AF diagnosis on
lifestyle change could not be analyzed, so the intentionality of changes in PA could not be
provided. To minimize this, we utilized two questionnaires that were closest to the date of
AF diagnosis. Fourth, the exact amount of time spent on daily exercise was not available if
it was over 30 min/day for MPA or 20 min/day for VPA, thereby leaving possibilities of in-
group differences among exercisers. This might affect an analysis that aimed to determine
the optimal frequencies of MVPA/week. In addition, a self-reported questionnaire only
focuses on aerobic exercise; therefore, information on non-aerobic exercise might be missing.
Fifth, the type and burden of AF were not accessible in the claims database and thus were
not evaluated in the study. Lastly, due to the data characteristics, the study was conducted
mainly in the Asian population; thus, further studies should be done in other population
groups for results to be verified and generalized.
5. Conclusions
In this large, population-based cohort study, patients with new-onset AF who initiated
or continued regular exercise were associated with a lower risk of incident dementia than
were persistent non-exercisers. Our findings may provide evidence for physicians of
exercise prescription to their patients newly diagnosed with AF, regardless of their current
exercise status, to prevent or delay the onset of incident dementia.
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